Osimertinib news

All news on Osimertinib (also known as Tagrisso): plants, production capacities, investments and involved companies.

17 December 2025

Johnson & Johnson's RYBREVANT FASPRO™ Gains FDA Approval for Faster NSCLC Treatment

FDA approves RYBREVANT FASPRO™ for EGFR-mutated NSCLC, offering faster, subcutaneous administration with fewer side effects compared to IV delivery.

Who will be producing Osimertinib in the future?

Find out with chemXplore Analytics